Literature DB >> 25830121

Eltrombopag: a new treatment option for chronic refractory adult immune thrombocytopenia.

Rojin Park1.   

Abstract

Entities:  

Year:  2015        PMID： 25830121      PMCID： PMC4377332          DOI： 10.5045/br.2015.50.1.1

Source DB:  PubMed          Journal:  Blood Res        ISSN： 2287-979X


× No keyword cloud information.
  10 in total

1.  A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.

Authors:  Y Tomiyama; Y Miyakawa; S Okamoto; S Katsutani; A Kimura; Y Okoshi; H Ninomiya; H Kosugi; S Nomura; K Ozaki; Y Ikeda; T Hattori; K Katsura; Y Kanakura
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

2.  Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.

Authors:  Robert McMillan; Lei Wang; Aaron Tomer; Janet Nichol; Jeanne Pistillo
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

Review 3.  How I treat idiopathic thrombocytopenic purpura (ITP).

Authors:  Douglas B Cines; James B Bussel
Journal:  Blood       Date:  2005-06-07       Impact factor: 22.113

4.  Thrombocytopenia caused by the development of antibodies to thrombopoietin.

Authors:  J Li; C Yang; Y Xia; A Bertino; J Glaspy; M Roberts; D J Kuter
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

5.  Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.

Authors:  Mansoor N Saleh; James B Bussel; Gregory Cheng; Oliver Meyer; Christine K Bailey; Michael Arning; Andres Brainsky
Journal:  Blood       Date:  2012-11-20       Impact factor: 22.113

Review 6.  New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.

Authors:  Alan T Nurden; Jean-François Viallard; Paquita Nurden
Journal:  Lancet       Date:  2009-03-25       Impact factor: 79.321

7.  Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile.

Authors:  Gregory Cheng
Journal:  Ther Adv Hematol       Date:  2012-06

8.  Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

Authors:  James B Bussel; Gregory Cheng; Mansoor N Saleh; Bethan Psaila; Lidia Kovaleva; Balkis Meddeb; Janusz Kloczko; Habib Hassani; Bhabita Mayer; Nicole L Stone; Michael Arning; Drew Provan; Julian M Jenkins
Journal:  N Engl J Med       Date:  2007-11-29       Impact factor: 91.245

9.  Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.

Authors:  David J Kuter; James B Bussel; Roger M Lyons; Vinod Pullarkat; Terry B Gernsheimer; Francis M Senecal; Louis M Aledort; James N George; Craig M Kessler; Miguel A Sanz; Howard A Liebman; Frank T Slovick; J Th M de Wolf; Emmanuelle Bourgeois; Troy H Guthrie; Adrian Newland; Jeffrey S Wasser; Solomon I Hamburg; Carlos Grande; François Lefrère; Alan Eli Lichtin; Michael D Tarantino; Howard R Terebelo; Jean-François Viallard; Francis J Cuevas; Ronald S Go; David H Henry; Robert L Redner; Lawrence Rice; Martin R Schipperus; D Matthew Guo; Janet L Nichol
Journal:  Lancet       Date:  2008-02-02       Impact factor: 79.321

10.  Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia.

Authors:  Yeo-Kyeoung Kim; Seung-Sin Lee; Sung-Hoon Jeong; Jae-Sook Ahn; Deok-Hwan Yang; Je-Jung Lee; Hyeoung-Joon Kim
Journal:  Blood Res       Date:  2015-03-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.